Standard BioTools Inc. (LAB) Earnings History
Net Loss20 years of earnings data (2006–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Standard BioTools Inc. (LAB) Earnings Overview
As of October 3, 2026, Standard BioTools Inc. (LAB) reported trailing twelve-month net income of -$87M, reflecting +61.5% year-over-year growth. The company earned $-0.22 per diluted share over the past four quarters, with a net profit margin of -87.8%.
Looking at the long-term picture, LAB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$16M in fiscal 2013.
Standard BioTools Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AZTA (-$123M net income, -9.4% margin), NTRA (-$192M net income, -9.0% margin), PACB (-$131M net income, -341.5% margin), LAB has room to improve margins relative to the peer group. Compare LAB vs AZTA →
LAB Earnings vs Peers
Earnings metrics vs comparable public companies
LAB Historical Earnings Data (2006–2025)
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$75M | +46.1% | -$93M | $-0.20 | -87.8% | -109.3% |
| 2024 | -$139M | -86.0% | -$175M | $-0.52 | -79.6% | -100.5% |
| 2023 | -$75M | +60.7% | -$77M | $-0.94 | -70.2% | -72.0% |
| 2022 | -$190M | -220.9% | -$116M | $-2.43 | -194.1% | -118.6% |
| 2021 | -$59M | -11.7% | -$67M | $-0.78 | -45.4% | -51.7% |
| 2020 | -$53M | +18.2% | -$51M | $-0.74 | -38.4% | -36.9% |
| 2019 | -$65M | -9.8% | -$52M | $-0.97 | -55.3% | -44.2% |
| 2018 | -$59M | +2.5% | -$48M | $-1.49 | -52.2% | -42.6% |
| 2017 | -$61M | +20.3% | -$58M | $-1.84 | -59.4% | -57.3% |
| 2016 | -$76M | -42.5% | -$73M | $-2.62 | -72.8% | -70.1% |
| 2015 | -$53M | -0.9% | -$50M | $-1.86 | -46.5% | -43.7% |
| 2014 | -$53M | -233.9% | -$52M | $-1.90 | -45.4% | -44.5% |
| 2013 | -$16M | +16.8% | -$18M | $-0.62 | -22.2% | -25.2% |
| 2012 | -$19M | +15.3% | -$18M | $-0.86 | -36.4% | -34.5% |
| 2011 | -$22M | -32.9% | -$19M | $-1.26 | -52.4% | -43.3% |
| 2010 | -$17M | +11.6% | -$15M | $-0.89 | -50.4% | -43.4% |
| 2009 | -$19M | +35.2% | -$18M | $-11.02 | -75.3% | -71.0% |
| 2008 | -$29M | -15.9% | -$30M | $-17.85 | -192.2% | -192.5% |
| 2007 | -$25M | -8.1% | -$24M | $-13.47 | -349.8% | -323.4% |
| 2006 | -$24M | - | -$22M | $-12.46 | -368.1% | -338.6% |
Download Data
Export LAB earnings history in CSV or JSON format
Free sign-in required to download data
LAB Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LAB — Frequently Asked Questions
Quick answers to the most common questions about buying LAB stock.
What is LAB earnings per share (EPS)?
LAB trailing twelve-month (TTM) diluted EPS is $-0.22, reflecting +61.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2006 to 2025 is available in the table on this page.
What is Standard BioTools Inc.'s net income?
Standard BioTools Inc. (LAB) trailing twelve-month net income is $-87M as of 2025. Earnings grew +61.5% year-over-year.
Is LAB profitable?
LAB is not currently profitable on a TTM basis, reporting a net loss of $-87M. Net margin is -87.8%. Investors should monitor for a return to profitability.
What is LAB's earnings growth rate?
LAB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2006 to 2025.
What are LAB's profit margins?
Standard BioTools Inc. net profit margin is -87.8%, operating margin is -109.3%, and gross margin is +49.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is -16.7%.
Is LAB growing earnings?
Yes, LAB earnings are accelerating — EPS growth of +61.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-87M. Earnings momentum is strengthening.
What was LAB's best earnings year?
Standard BioTools Inc.'s highest annual net income on record is $-16M, achieved in fiscal year 2013. Earnings history on this page spans 2006 to 2025 and includes all annual and quarterly figures.
What were LAB's earnings last quarter?
LAB's most recent reported quarter was Q2 2026. Net income was $-27M with diluted EPS of $-0.07. For a full breakdown of all quarters, see the quarterly earnings table on this page.